Starting a GLP-1 medication in this context requires transparent monitoring for whether nausea, diarrhea, or abdominal discomfort is baseline post-surgical variation or a medication response
Phase 1b (CT-388, 24 weeks): Phase 2 (CT-388 up to 24 mg, 48 weeks): GI AEs described as "mild-to-moderate" and "generally consistent with incretin class" Discontinuation due to AEs: 5.9% (vs 1.3% placebo) Weight loss: 22.5% placebo-adjusted at 48 weeks Key characteristics: Phase 1b showed very high absolute GI rates during titration, but these declined substantially during maintenance Phase 2 data showed a much more favorable tolerability profile with a low discontinuation rate of 5.9% The signal-biased design appears to provide sustained receptor activation without desensitization Despite high initial GI rates, very few patients discontinued, suggesting events were transient and manageable Phase 3 (ENITH program) planned for 2026 Bioglutide (NA-931)# Bioglutide is the first oral quadruple receptor agonist (GLP-1, GIP, glucagon, and IGF-1), developed by Biomed Industries
Liu W, Zhou W, Zhao P, Wu T, Gu H, Li Y, Zhong C, Bai H, Zhao N, Huang X (2025) PD-Like pathogenesis in Caenorhabditis elegans intestinally infected with Nocardia farcinica and the underlying molecular mechanisms
She ran one mile a day for a month A few years later, Brown got bored with walking and wanted to try running
